Molecular Subtypes and Genomic Characteristics of Primary CNS Lymphoma

Overview

This study analyzed whole-exome sequencing data from 140 Chinese patients with primary central nervous system lymphoma (PCNSL) to delineate its genomic landscape and define three molecular subtypes based on single-nucleotide variations. These subtypes are associated with distinct clinical outcomes, providing a potential framework for precision oncology in PCNSL.

Background

Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-Hodgkin lymphoma with poor prognosis despite high-dose methotrexate-based treatment. PCNSL is genetically heterogeneous and molecularly distinct from systemic diffuse large B-cell lymphoma (DLBCL), which complicates the application of existing DLBCL molecular classifications. Previous studies have identified molecular patterns in PCNSL, but data on Chinese patients remain limited, necessitating comprehensive genomic profiling to inform targeted therapies.

Data Highlights

Key Findings

• PCNSL tumors from 140 Chinese patients were genomically profiled using WES, with an additional 36 patients analyzed by WES/WGS as an external cohort.
• Three molecular subtypes of PCNSL were defined based solely on single-nucleotide variations, each correlating with distinct clinical outcomes.
• PCNSL is molecularly distinct from systemic DLBCL, underscoring the need for PCNSL-specific classification schemes.
• The study confirmed the genomic heterogeneity of PCNSL in Chinese patients, highlighting ethnic differences in molecular characteristics.
• All patients received high-dose methotrexate-based combination immunochemotherapy, with some receiving additional agents such as rituximab, idarubicin, or BTK inhibitors.
• Long-term follow-up was conducted to assess clinical outcomes related to molecular subtypes.

Clinical Implications

The identification of three molecular subtypes of PCNSL based on SNVs offers a potential framework for personalized treatment strategies in Chinese patients. Incorporating molecular classification into clinical practice may improve prognostication and guide the use of targeted therapies alongside standard high-dose methotrexate regimens. Further validation in diverse populations is needed to generalize these findings.

Conclusion

This comprehensive genomic study of Chinese PCNSL patients reveals distinct molecular subtypes with prognostic significance, providing a foundation for precision oncology approaches tailored to PCNSL’s unique biology. These findings may facilitate subtype-based targeted interventions to improve patient outcomes.

References

1. W.L. Zhao et al. 2023 -- Molecular Subtypes and Genomic Characteristics of Primary Central Nervous System Lymphoma